Bayer +4.45%: litigation resolution or pipeline catalyst imminent?
Bayer AG's 4.45% single-session gain to €62.00 is the DAX session's headline surprise. Major single-day pharmaceutical moves without a publicly announced catalyst typically precede a material event within 24-48 hours — litigation settlement, clinical trial readout, or strategic partnership. Bayer has significant legacy litigation exposure from Monsanto-Roundup glyphosate cases, and any settlement progress would unlock the balance sheet overhang that has suppressed valuation for three years. A confirmed settlement would be the most significant positive re-rating event for the stock since the 2018 Monsanto acquisition. DAX-40 investors should monitor any regulatory filing with SEC or German courts in the next 48 hours.
Read at Yahoo Finance ↗